189 related articles for article (PubMed ID: 20233883)
41. Predicting clinical outcome through molecular profiling in stage III melanoma.
John T; Black MA; Toro TT; Leader D; Gedye CA; Davis ID; Guilford PJ; Cebon JS
Clin Cancer Res; 2008 Aug; 14(16):5173-80. PubMed ID: 18698035
[TBL] [Abstract][Full Text] [Related]
42. [Prognosis of primary cutaneous lymphomas].
Grange F; Bagot M
Ann Dermatol Venereol; 2002 Jan; 129(1 Pt 1):30-40. PubMed ID: 11937927
[TBL] [Abstract][Full Text] [Related]
43. Long-term follow-up of patients with early-stage cutaneous T-cell lymphoma who achieved complete remission with psoralen plus UV-A monotherapy.
Querfeld C; Rosen ST; Kuzel TM; Kirby KA; Roenigk HH; Prinz BM; Guitart J
Arch Dermatol; 2005 Mar; 141(3):305-11. PubMed ID: 15781671
[TBL] [Abstract][Full Text] [Related]
44. Analysis of clonality in cutaneous T cell lymphoma and associated diseases.
Wood GS
Ann N Y Acad Sci; 2001 Sep; 941():26-30. PubMed ID: 11594579
[TBL] [Abstract][Full Text] [Related]
45. Serological immunomarkers in cutaneous T cell lymphoma.
Hassel JC; Meier R; Joller-Jemelka H; Burg G; Dummer R
Dermatology; 2004; 209(4):296-300. PubMed ID: 15539892
[TBL] [Abstract][Full Text] [Related]
46. Genotypic analysis of cutaneous T-cell lymphoma: a comparative study of Southern blot analysis with polymerase chain reaction amplification of the T-cell receptor-gamma gene.
Curcó N; Servitje O; Llucià M; Bertran J; Limón A; Carmona M; Romagosa V; Peyrí J
Br J Dermatol; 1997 Nov; 137(5):673-9. PubMed ID: 9415223
[TBL] [Abstract][Full Text] [Related]
47. Cutaneous T cell lymphoma: the helping hand of dendritic cells.
Edelson RL
Ann N Y Acad Sci; 2001 Sep; 941():1-11. PubMed ID: 11594563
[TBL] [Abstract][Full Text] [Related]
48. Primary cutaneous small/medium CD4+ T-cell lymphomas: a heterogeneous group of tumors with different clinicopathologic features and outcome.
Garcia-Herrera A; Colomo L; Camós M; Carreras J; Balague O; Martinez A; Lopéz-Guillermo A; Estrach T; Campo E
J Clin Oncol; 2008 Jul; 26(20):3364-71. PubMed ID: 18541895
[TBL] [Abstract][Full Text] [Related]
49. Transcriptional response of T cells to IFN-alpha: changes induced in IFN-alpha-sensitive and resistant cutaneous T cell lymphoma.
Tracey L; Spiteri I; Ortiz P; Lawler M; Piris MA; Villuendas R
J Interferon Cytokine Res; 2004 Mar; 24(3):185-95. PubMed ID: 15035852
[TBL] [Abstract][Full Text] [Related]
50. Expression of interleukin-18 and caspase-1 in cutaneous T-cell lymphoma.
Yamanaka K; Clark R; Dowgiert R; Hurwitz D; Shibata M; Rich BE; Hirahara K; Jones DA; Eapen S; Mizutani H; Kupper TS
Clin Cancer Res; 2006 Jan; 12(2):376-82. PubMed ID: 16428475
[TBL] [Abstract][Full Text] [Related]
51. Clonal T-cell receptor gamma-chain gene rearrangement by PCR-based GeneScan analysis in advanced cutaneous T-cell lymphoma: a critical evaluation.
Dippel E; Assaf C; Hummel M; Schrag HJ; Stein H; Goerdt S; Orfanos CE
J Pathol; 1999 Jun; 188(2):146-54. PubMed ID: 10398157
[TBL] [Abstract][Full Text] [Related]
52. Health-related quality-of-life assessment in patients with cutaneous T-cell lymphoma.
Demierre MF; Tien A; Miller D
Arch Dermatol; 2005 Mar; 141(3):325-30. PubMed ID: 15781673
[TBL] [Abstract][Full Text] [Related]
53. Prognostic value of blood eosinophilia in primary cutaneous T-cell lymphomas.
Tancrède-Bohin E; Ionescu MA; de La Salmonière P; Dupuy A; Rivet J; Rybojad M; Dubertret L; Bachelez H; Lebbé C; Morel P
Arch Dermatol; 2004 Sep; 140(9):1057-61. PubMed ID: 15381544
[TBL] [Abstract][Full Text] [Related]
54. T-Cell Receptor Gene Rearrangement Clonality, Flow Cytometry Status, and Associated Outcomes in Early-Stage Cutaneous T-Cell Lymphoma.
Marks JA; Switchenko JM; Martini DJ; Tarabadkar ES; Khan MK; Lechowicz MJ; Allen PB
JAMA Dermatol; 2021 Aug; 157(8):954-962. PubMed ID: 34190977
[TBL] [Abstract][Full Text] [Related]
55. Quantitative flow cytometric identification of aberrant T cell clusters in erythrodermic cutaneous T cell lymphoma. Implications for staging and prognosis.
Horna P; Deaver DM; Qin D; Moscinski LC; Sotomayor EM; Glass LF; Sokol L
J Clin Pathol; 2014 May; 67(5):431-6. PubMed ID: 24319102
[TBL] [Abstract][Full Text] [Related]
56. Evaluation of the efficacy of the combination of oral bexarotene and methotrexate for the treatment of early stage treatment-refractory cutaneous T-cell lymphoma.
Kannangara AP; Levitan D; Fleischer AB
J Dermatolog Treat; 2009; 20(3):169-76. PubMed ID: 19016373
[TBL] [Abstract][Full Text] [Related]
57. Cutaneous T-cell lymphoma: from genetics to clinical practice.
Dummer R; Zucca E
Oncology (Williston Park); 2007 Feb; 21(2 Suppl 1):7-8. PubMed ID: 17474352
[No Abstract] [Full Text] [Related]
58. Expression of MCM-3 and MCM-7 in Primary Cutaneous T-cell Lymphomas.
Jankowska-Konsur A; Kobierzycki C; Reich A; Grzegrzolka J; Maj J; Dziegiel P
Anticancer Res; 2015 Nov; 35(11):6017-26. PubMed ID: 26504025
[TBL] [Abstract][Full Text] [Related]
59. [Therapy of cutaneous T-cell lymphomas].
Rappersberger K; Ortel B; Forstinger C; Wolff K
Wien Klin Wochenschr; 1994; 106(10):300-8. PubMed ID: 8053197
[TBL] [Abstract][Full Text] [Related]
60. Molecular staging of lymph nodes from 60 patients with mycosis fungoides and Sézary syndrome: correlation with histopathology and outcome suggests prognostic relevance in mycosis fungoides.
Fraser-Andrews EA; Mitchell T; Ferreira S; Seed PT; Russell-Jones R; Calonje E; Whittaker SJ
Br J Dermatol; 2006 Oct; 155(4):756-62. PubMed ID: 16965425
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
